AU2021236757A1 - Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof - Google Patents

Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof Download PDF

Info

Publication number
AU2021236757A1
AU2021236757A1 AU2021236757A AU2021236757A AU2021236757A1 AU 2021236757 A1 AU2021236757 A1 AU 2021236757A1 AU 2021236757 A AU2021236757 A AU 2021236757A AU 2021236757 A AU2021236757 A AU 2021236757A AU 2021236757 A1 AU2021236757 A1 AU 2021236757A1
Authority
AU
Australia
Prior art keywords
brequinar
hours
sodium salt
cancer
brequinar sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021236757A
Other languages
English (en)
Inventor
Lin Cui
Chaoyi DENG
David P. Hesson
Ping Huang
Mo JIA
Siyi Jiang
Qingqing LU
Abdolsamad Tadayon
Jinsuo YANG
Xianjun You
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clear Creek Bio Inc
Original Assignee
Clear Creek Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clear Creek Bio Inc filed Critical Clear Creek Bio Inc
Publication of AU2021236757A1 publication Critical patent/AU2021236757A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021236757A 2020-03-20 2021-03-19 Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof Pending AU2021236757A1 (en)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202062992720P 2020-03-20 2020-03-20
US62/992,720 2020-03-20
US202063020460P 2020-05-05 2020-05-05
US63/020,460 2020-05-05
US202063030677P 2020-05-27 2020-05-27
US63/030,677 2020-05-27
US202063043382P 2020-06-24 2020-06-24
US202063043386P 2020-06-24 2020-06-24
US202063043388P 2020-06-24 2020-06-24
US202063043384P 2020-06-24 2020-06-24
US63/043,384 2020-06-24
US63/043,388 2020-06-24
US63/043,386 2020-06-24
US63/043,382 2020-06-24
PCT/US2021/023350 WO2021189017A1 (en) 2020-03-20 2021-03-19 Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof

Publications (1)

Publication Number Publication Date
AU2021236757A1 true AU2021236757A1 (en) 2022-10-13

Family

ID=77771654

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021236757A Pending AU2021236757A1 (en) 2020-03-20 2021-03-19 Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof

Country Status (5)

Country Link
EP (1) EP4121050A4 (https=)
JP (1) JP2023518419A (https=)
AU (1) AU2021236757A1 (https=)
CA (1) CA3175964A1 (https=)
WO (1) WO2021189017A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159763A1 (en) * 2021-01-22 2022-07-28 Model Medicines, Inc. Sars-cov-2 therapeutics
WO2023043830A1 (en) * 2021-09-15 2023-03-23 Clear Creek Bio, Inc. Combination therapies to treat viral infections
CN120131690A (zh) * 2025-03-24 2025-06-13 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 一种布喹那在制备抑制流感病毒的制剂中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05011525A (es) * 2003-04-30 2005-12-12 Nippon Shinyaku Co Ltd Cristales de solvato de derivado de acido quinolincarboxilico.
CA2910112C (en) * 2013-04-25 2021-02-16 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
US11096934B2 (en) * 2015-09-01 2021-08-24 The Broad Institute, Inc. Compounds and methods useful for treating or preventing hematological cancers
EP3773579A4 (en) * 2018-03-26 2022-03-09 Clear Creek Bio, Inc. COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
US20190290634A1 (en) * 2018-03-26 2019-09-26 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
WO2019246603A1 (en) * 2018-06-22 2019-12-26 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase

Also Published As

Publication number Publication date
JP2023518419A (ja) 2023-05-01
EP4121050A1 (en) 2023-01-25
CA3175964A1 (en) 2021-09-23
WO2021189017A1 (en) 2021-09-23
EP4121050A4 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
US12076315B2 (en) Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
US20230241045A1 (en) Methods of treatment for cystic fibrosis
TWI786110B (zh) (s)-2-乙基丁基2-(((s)-(((2r,3s,4r,5r) -5-(4-胺基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基-3,4-二羥基四氫呋喃-2-基)甲氧基)(苯氧基)磷醯基)胺基)丙酸酯之結晶形式
AU2021236757A1 (en) Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
WO2019018353A1 (en) METHODS OF TREATING CYSTIC FIBROSIS
CN110092745B (zh) 一种含芳环的化合物及其应用
JP2019526605A (ja) 置換２−ｈ−ピラゾール誘導体の結晶形、塩型及びその製造方法
CN105732615A (zh) Cdk激酶抑制剂
KR102434764B1 (ko) 간 전송 항바이러스 전구체 약물 뉴클레오시드 시클로 포스페이트 에스테르 화합물 및 응용
CN109651377A (zh) 一种治疗癌症的化合物及其用途
CN105820130B (zh) 三氮唑正丙酸类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途
KR20060127906A (ko) 4'-치환된 카보버와 아바카비어 유도체 및 ｈｉｖ와 ｈｃｖ항바이러스 활성을 갖는 관련 화합물
SA06270462B1 (ar) مركبات وطرق لتثبيط التفاعل بين بروتين bcl وشركاء الارتباط
CN120247920A (zh) 一种PARP/CK2α双靶点激酶抑制剂小分子及其药物组合物和应用
TWI769395B (zh) 以吡唑并[3,4-d]嘧啶化合物為有效成分之治療劑
WO2013123745A1 (zh) 齐多夫定喹啉共轭化合物及其制备方法和抗肝癌之应用
CN116284179B (zh) 淫羊藿次苷ii衍生物的制备及应用
CN115322120B (zh) 一类小分子化合物及在制备治疗dhodh介导疾病药物中的用途
CN114105888B (zh) 丙基硫氧嘧啶与具有抗氧化活性的营养素小分子的共晶及其制备方法
CN116239570B (zh) 一种半琥珀酸拉司米地坦新晶型
WO2019149090A1 (zh) 一种尿酸转运体1抑制剂的晶体及其制备方法和用途
CN113825758B (zh) 抗HBV的四氢异噁唑并[4,3-c]吡啶类化合物的晶型
CN115819349A (zh) 一种吡唑类化合物及其制备方法和应用
WO2024098856A1 (zh) 一种抗流感病毒衍生物及其用途
CN108290842B (zh) 一种取代的喹啉化合物及其药物组合物